Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial

RCT (n=268 in South Africa & Uganda) reported more women treated with dolutegravir met primary endpoint (viral load <50 copies/mL at first post-partum visit) vs those on efavirenz (74% vs 43%; RR 1.64, 95% CI 1.31–2.06), but with more serious adverse events (22% vs 11%; p=0.013).

SPS commentary:

The authors note that these findings support the revision to WHO guidelines recommending the transition to dolutegravir in first-line antiretroviral therapy for all adults, regardless of pregnancy or child-bearing potential.


The Lancet HIV